Covid-19 | Serum Institute of India seeks indemnity protection: ReportThis comes a day after reports that Pfizer and Moderna were also close to an indemnity deal
Last Updated IST
dar Poonawalla, Chief Executive Officer (CEO) of the Serum Institute of India. Credit: Reuters File Photo
The Serum Institute of India (SII), which manufactures AstraZeneca and Oxford University's Covid-19 vaccine — Covishield, has sought indemnity protection against liabilities, news agency ANI reported citing sources familiar with the matter.
ANI on Wednesday reported that Pfizer and Moderna were a step closer to indemnity deals with the government of India.
The pharma giants had sought from the government indemnity from costs relating to severe vaccine side-effects. India's apex drug regulator has also waived the requirement of testing every batch of foreign-made Covid-19 vaccines and conducting bridging trials for vaccines approved by the WHO.
More details awaited.